ORLANDO, Fla. — At this year’s Community Oncology Alliance (COA) Annual Meeting, AllyGPO and BioCareSD showcased a powerful partnership aimed at redefining how independent oncology practices manage and receive specialty medications. Through a shared commitment to innovation and technology, the two companies are delivering advanced tools and streamlined drug distribution designed specifically to meet the evolving needs of community-based cancer care.
Central to the collaboration is AllyIQ, AllyGPO’s specialty drug management platform built exclusively for community oncology practices. The system integrates intelligent inventory tools—including the first fully smart drug cabinet—with role-based workflows and real-time business intelligence. Already in use across the country, AllyIQ enables oncology practices to efficiently manage drug supply, optimize purchasing through group purchasing organization (GPO) contracts, and reduce administrative burdens.
“AllyIQ represents our commitment to bringing true technological innovation to community oncology,” said Stuart McMahan, Chief Information Officer at AllyGPO. “We’re helping practices improve drug management and streamline operations so they can focus more on patient care.”
Supporting this tech-forward ecosystem is BioCareSD, which is modernizing specialty drug distribution with sustainable packaging, precision logistics, and a flexible delivery infrastructure. Its platform ensures the reliable, temperature-controlled shipment of life-saving cancer therapies while minimizing environmental impact.
“BioCareSD is dedicated to transforming specialty distribution,” said Cory Shouse, CIO of BioCare. “Our system is designed to meet the high standards of today’s oncology practices, delivering both speed and reliability. When integrated with AllyIQ, it creates a seamless, efficient experience for our shared customers.”
The integration between AllyIQ and BioCareSD’s ordering platform is further enhanced by the system’s compatibility with existing electronic health record and practice management software. This connectivity gives practices access to timely data on drug utilization and economics without requiring a costly overhaul of legacy systems. Both companies emphasize that their platforms are built from the ground up using modern, cloud-native technology—free of the technical debt that often hampers innovation in healthcare IT.
“The agility of our systems is a game-changer,” said McMahan. “We can respond to practice needs and market shifts in days, not months. In a field as fast-moving as oncology, that kind of responsiveness is essential.”
AllyGPO and BioCareSD say their collaboration is built on a shared vision: to empower independent oncology practices with better tools, smarter insights, and greater operational support. That vision extends beyond technology to include service and consultative expertise from teams focused solely on oncology.
“Our commitment to innovation is fundamentally improving the way community oncology practices operate,” said Brian Ansay, CEO of AllyGPO. “Together with BioCareSD, we’re delivering intelligence, efficiency, and value to practices that need to stay independent and agile in an increasingly complex healthcare landscape. We’re not just adapting to change—we’re leading it.”
